Page 6 - Nasdaq Mltx News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Nasdaq mltx. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Nasdaq Mltx Today - Breaking & Trending Today

MoonLake Immunotherapeutics (NASDAQ:MLTX) Research Coverage Started at Needham & Company LLC

Needham & Company LLC started coverage on shares of MoonLake Immunotherapeutics (NASDAQ:MLTX – Free Report) in a report issued on Thursday, Marketbeat Ratings reports. The brokerage issued a buy rating and a $76.00 target price on the stock. Several other research firms have also recently issued reports on MLTX. Wedbush reaffirmed an outperform rating and […] ....

Moonlake Immunotherapeutics , Bihua Chen , Citadel Advisors , Pricet Rowe Associates Inc , Cantor Fitzgerald , Needham Company , Millennium Management , Securities Exchange Commission , Free Report , Marketbeat Ratings , Moderate Buy , Get Free Report , Exchange Commission , Pricet Rowe Associates , Nasdaq Mltx , Initiated Coverage , Needham Company Llc ,

Q3 2023 EPS Estimates for MoonLake Immunotherapeutics (NASDAQ:MLTX) Lifted by Analyst

MoonLake Immunotherapeutics (NASDAQ:MLTX – Free Report) – Research analysts at HC Wainwright lifted their Q3 2023 EPS estimates for shares of MoonLake Immunotherapeutics in a research note issued on Monday, August 14th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings of ($0.23) per share for the quarter, up from their […] ....

Moonlake Immunotherapeutic , Bihua Chen , Moonlake Immunotherapeutics , Century Group , Citadel Advisors , Cantor Fitzgerald , Pricet Rowe Associates Inc , Moonlake Immunotherapeutics Company Profile , Free Report , Get Free Report , Asset Management , Nasdaq Mltx , Earnings Estimates , Hc Wainwright ,

HC Wainwright Reaffirms "Buy" Rating for MoonLake Immunotherapeutics (NASDAQ:MLTX)

MoonLake Immunotherapeutics (NASDAQ:MLTX – Get Free Report)‘s stock had its “buy” rating reaffirmed by equities researchers at HC Wainwright in a research note issued to investors on Monday, Benzinga reports. They presently have a $75.00 target price on the stock. HC Wainwright’s price objective would indicate a potential upside of 30.78% from the company’s current […] ....

Moonlake Immunotherapeutics , Bihua Chen , Securities Exchange Commission , Century Group , Cantor Fitzgerald , Citadel Advisors , Pricet Rowe Associates Inc , Millennium Management , Get Free Report , Exchange Commission , Pricet Rowe Associates , Nasdaq Mltx , Reiterated Rating , Hc Wainwright ,

MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives "Buy" Rating from HC Wainwright

MoonLake Immunotherapeutics (NASDAQ:MLTX – Get Free Report)‘s stock had its “buy” rating reiterated by equities researchers at HC Wainwright in a note issued to investors on Monday, Benzinga reports. They presently have a $75.00 price target on the stock. HC Wainwright’s price target suggests a potential upside of 30.78% from the stock’s previous close. Several […] ....

Moonlake Immunotherapeutics , Bihua Chen , Moonlake Immunotherapeutics Company Profile , Securities Exchange Commission , Hermes Inc , Citadel Advisors , Pricet Rowe Associates Inc , Blackrock Inc , Get Free Report , Exchange Commission , Nasdaq Mltx , Reiterated Rating , Hc Wainwright ,

MoonLake Immunotherapeutics (NASDAQ:MLTX) Given Consensus Recommendation of "Moderate Buy" by Analysts

MoonLake Immunotherapeutics (NASDAQ:MLTX – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the ten research firms that are covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating and nine have given a buy rating to the company. The average 12-month price target among brokers […] ....

United States , Bihua Chen , Moonlake Immunotherapeutics , Geode Capital Management , Osaic Holdings Inc , Renaissance Technologies , Goldman Sachs Group Inc , America Corp , Cantor Fitzgerald , Get Free Report , Marketbeat Ratings , Sachs Group , Capital Management , Get Free , Nasdaq Mltx ,